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Abstract MicroRNAs (miRNA) are a large family of containing miR-16 precursor sequence. The effects of 
small single-stranded RNA molecules found in all multi­ ectopic expression of miR-16 on breast cancer phenotype 
cellular organisms. Early studies have been shown that were examined by cell cycle analysis and apoptosis as­
miRNA are involved in cancer development and progres­ says. miR-16 cytotoxicity effect was measured by the 
sion, and this role can be done by working as an onco­ MTT assay. We showed that the miR-16 overexpression 
genes and tumor suppressor genes, so manipulation of reduces  Cyclin  D1 and BCL2 at  messenger  RNA 
this molecules can be a promising approach in cancer (mRNA) and protein levels in MCF-7 cell line. In addi­
therapy, and experimental results represented that the tion, this is found that enforced expression of miR-16 
modification in breast cancer phenotype is possible by decreases cell growth and proliferation and induces apo­
miRNA expression alteration. miR-16, which is located ptosis in MCF-7 cells. In conclusion, our results revealed 
in 13q14 chromosome, plays critical roles as a tumor that upregulation of miR-16 would be a potential ap­
suppressor by targeting several oncogenes which regulate proach for breast cancer therapy. 
cell cycle and apoptosis. Hence, in the present study, we 
investigated whether miR-16 could decline growth and 
survival of MCF-7 cell line as model of human breast Keywords MCF-7 .miR-16 .Cell cycle . Tumor suppressor . 
cancer. MCF-7 cell line was infected with lentiviruses Oncogene 
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Introduction 
Breast cancer is the most prevalent cancer in the women that 
originates from breast tissue and can be a result from muta­
tions on several tumor suppressor genes including BRCA1, 
BRCA2, p53, ATM, and PTEN (Buchholz and Wazer 2002). 
Today, with thanks from miRNA biology, cancer researchers 
have been able to achieve many dark aspects of breast cancer 
(He and Hannon 2004; Filipowicz  et al. 2008). MicroRNAs 
(miRNAs) are a novel class of small noncoding regulatory 
RNAs which control gene expression at post-transcriptional 
levels (Kouhkan et al. 2013; Kouhkan  et al. 2014). MiRNAs 
play critical roles in various cellular processes such as growth, 
apoptosis, metabolism, and survival of the cells (Bartel 2004; 
Kloosterman and Plasterk 2006; Bushati and Cohen 2007; 
Rana 2007). Official miRBase database lists that up to 30% 
of protein-coding genes in human genome is controlled by 
miRNAs (Griffiths-Jones et al. 2006). With regard to crucial 
roles of miRNAs, their expressions have been completely 
controlled in different organs. Recent studies have indicated 
that miRNAs can function as tumor suppressors and onco­
genes and any changes in their expression correlate with var­
ious human cancers such as lung cancer, prostate cancer, 
breast cancer, gastric cancer, and leukemia (Michael et al. 
2003; Takamizawa et al. 2004; Cimmino et al. 2005; 
Hayashita et al. 2005; Iorio et al. 2005; Deng  et al. 2008; 
Schetter et al. 2008; Golestaneh et al. 2012). Oncogenic 
miRNAs cause reduction in expression of the tumor suppres­
sor genes and/or genes that are implicated in cellular differen­
tiation, whereas tumor suppressor miRNAs lead to reduction 
in the expression levels of oncogenic genes involved in pro­
liferation and apoptosis (Calin and Croce 2006; Cho  2007; 
Barbarotto et al. 2008; Shenouda and Alahari 2009). The first 
experimental evidence indicating miR-16 involvement in 
mammalian carcinogenesis was reported by Calin et al. in B­
cell chronic lymphocytic leukemia (CLL) (Calin et al. 2008). 
Further investigation indicated that miR-16 was frequently 
deleted and/or downregulated in solid tumors including breast 
cancer, suggesting that this miRNA might be important for 
tumorigenesis (Calin et al. 2002; Bonci et al. 2008; Rivas 
et al. 2012). miR-16, as an important tumor suppressor, can 
participate in cell-cycle regulation in several tumor cell lines 
by targeting cyclin D (CCND) and  E (CCNE) and in the in­
duction of apoptosis by targeting BCL2 (Linsley et al. 2007; 
Liu et al. 2008). Cyclin E1 (CCNE1) and Cyclin D1 
(CCND1) are vital proteins that are synthesized during G1 
phase of cell cycle driving the G1/S phase transition. Aberrant 
expression of these oncogenes has been observed in many 
tumors, which results in chromosome instability, and thus 
may contribute to tumorogenesis (Ekholm and Reed 2000; 
Sandhu and Slingerland 2000; Grillo  et al. 2006; Alao  2007; 
Carleton et al. 2007). On the other hand, anti-apoptotic B-cell 
lymphoma 2 (BCL2) is a critical regulator in mitochondrial 
pathway inhibition of apoptosis in eukaryotic cells, conse­
quently, facilitating their survival (Cory and Adams 2002; 
Guo et al. 2009). Therefore, miR-16 could consider as most 
important tumor suppressor miRNA. Due to the fact that 
breast cancer is the most common invasive cancer and the 
second leading cause of the cancer death in women (Tinoco 
et al. 2013). 
The aim of this study was to investigate whether miR-16 
expression modulation could influence growth and survival of 
the breast tumor cells. Our data indicated that enforced expres­
sion of miR-16 in MCF-7 cells considerably reduced tumor 
growth and induced apoptosis. So, ectopic expression of 
miR16 could be utilized as a novel therapeutic approach in 
breast cancer. 
Materials and Methods 
Cell culture. Human breast cancer MCF-7 cell line and hu­
man embryonic kidney (HEK) 293 cell lines were obtained 
from Pasteur Institute of Iran and cultured in high-glucose 
Dulbecco’s modified Eagle medium (DMEM, Gibco BRL, 
Grand Island, NY) supplemented with 10% Fetal Bovine Se-
rum (FBS, Gibco) and 1% nonessential  amino acids 
(Invitrogen, Waltham, MA), penicillin (100 U/mL, Gibco), 
streptomycin (0.1 mg/mL, Gibco), and L-glutamine (2 mM, 
Gibco). Cells were cultured under standard condition in 95% 
humidity and 5% CO2 at 37°C. 
Recombinant lentivirus generation. A 458-bp DNA fragment 
containing the miR-16 precursor sequence was targeted for 
PCR amplification from human genomic DNA (Cinnagen, 
Tehran, Iran) by the following primers: forward: 5′-ACTC 
TAGAGCAGCACATAATGGTTTG-3′ and reverse: 5′­
TGGATCCCTCTAATGCTGCATAAGC-3′; the  XbaI and 
BamHI recognition sites were included. The amplified prod­
uct was cloned into a pCDH-CMV-MCS-EF1-copGFP vector 
(System Biosciences, Mountain View, CA). Inclusion of the 
green fluorescent protein (GFP) gene in the vector smooths 
the tracking of any transduction in subsequent experiments 
(Supplementary Fig. 1). Lentiviral system expressing miR­
16 precursor or control vector, as well as a lentiviral packaging 
system produced based on before, in brief generation of len­
tivirus performed at ∼50–60% confluency HEK which cul­
tured in cell expansion media (DMEM media supplemented 
with 10% FBS) on 10-cm plates. Transfection was performed 
with 10 μg of recombinant miR-16 lentivector plasmid, 10 μg 
of packaging plasmid pPAX2, and 5 μg of envelop plasmid 
pMD2. The medium was replaced with new culture medium 
12 h after transfection; then, viral supernatants were harvested 
36, 48, and 72 h after transfection. Collected viruses were 
centrifuged using ultracentrifuge at 25,000 rpm for 2.5, flash 
frozen and stored at  −80°C. For downregulation of  
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endogenous miR-16, pLenti-III-miR-Off-16 construct was 
purchased from ABM Company (Richmond, Canada) and 
packaged into lentivirus particles (recombinant anti-miR-16) 
as mentioned above. 
Transduction of MCF-7 cells with miR-16 containing 
lentiviruses. For lentiviral transduction, 2×105 cells were 
seeded in 6 cm2 culture plates and the following day trans­
duced with MOI 5 (TU/cell) of recombinant miR-16 lentivi­
rus. Forty-eight hours post-transduction, the cells were select­
ed with puromycin at 2 mg/mL. Efficiency of transduction 
was also confirmed by flow cytometry (Supplementary 
Fig. 2). Empty lentivirus was utilized as a negative control 
for the infection experiments. So, study was performed in 
three different groups. First, blank control group (the group 
that was untreated); second, test groups (the group infected by 
recombinant miR-16 viruses or anti-miR-16); and third, neg­
ative control groups (the group infected with nonrecombinant 
miR-16 or anti-miR-16 viruses). For anti-miR studies, MCF-7 
cells were seeded in 24-well plate and transduced following 
day with recombinant anti-miR-16 viruses. 
qRT-PCR for miRNA expression. Total RNA were extracted 
36 h after infection, from all kind of samples according to the 
manufacturer’s instruction for total RNA extraction kit 
(Bioneer, Daejeon, Korea). Real-time PCR for miR-16 was 
performed using Startagen kit (Stratagene, La Jolla, CA) ac­
cording to the manufacturer’s protocol. Briefly, total RNAwas 
polyadenylated by poly(A) polymerase. Then, reverse tran­
scription was performed using poly(A)-tailed total RNA, gen­
eral RT primer, and reverse transcriptase according to the 
manufacturer ’s protocol. Finally, relative fold changes of 
miR-16 expression in the test group against blank control 
group were calculated using the comparative CT (2−ΔΔCT) 
method with U6 small nuclear RNA (snRNA) as internal con­
trol. All of the experiments were carried out in triplicate. 
cDNA synthesis and real time PCR for miR-16 targets. Total 
RNA was extracted and complementary DNA (cDNA) syn­
thesis performed using Takara Reverse Transcriptase System 
(TaKaRa, Otsu, Japan); then the RT-PCR products (cDNA) 
were used for real-time PCR according to the manufacturer’s 
instruction. Expression level of cyclin D1 (CCND1) as impor­
tant cell cycle target of miR-16 was analyzed using real-time 
PCR (ABI, Grand Island, NY) by SYBER premix ExTaq kit 
(TaKaRa). Comparative CT (2−ΔΔCT) analysis was used to 
indicate the quantitative expression of target gene related to 
GAPDH as an endogenous control to standardize amount of 
RNA samples. The following primers were used for QRT­
PCR reactions, CCND1 FW: 5′-CCGTCCATGCGGAAGA 
TC-3′, CCND1 RW: 5′-GAAGACCTCCTCGCACT-3′; 
GAPDH FW: 5′-GACAAGCTTCCCGTTCTCAG-3 ′, 
GAPDH RW: 5′-GAGTCAACGGAT-TTGGTCGT-3′. 
Western blot. Whole-cell proteins were extracted with cell 
lysis buffer (50 Mm Tris, pH=8.0, 150 mM NaCl, 1% NP­
40, 0.5% sodium deoxycholate, 1 mM sodium fluoride, 1 mM 
sodium orthovanadate, 1 mM EDTA) and resolved by 10% 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The 
proteins were transferred onto polyvinylidene fluoride mem­
brane (PDVF, pore size 0.45 mm; Millipore, Billerica, MA) 
with a semi-dry transfer cell (Model 755, Bio-Rad, Hercules, 
CA) for 1.5 h at 80 A at room temperature. Then, the mem­
brane was immersed in 5% nonfat milk powder over 2 h. 
When finished, the membrane was incubated with anti­
BCL2, anti-CCND1, and anti-GAPDH antibody. The mem­
brane was further probed with horseradish peroxidase (HRP)­
conjugated goat anti-(rabbit Ig) antibody (Sigma, St. Louis, 
MO). The protein bands were visualized using (ECL®) detec­
tion kit (Pierce. Rockford, IL). Finally, chemiluminescence 
was captured on Kodak X-film (Tokyo, Japan). 
Growth curve. MCF-7 cells were seeded into six-well plate 
and infected with recombinant or nonrecombinant miR-16 
viruses (control) particles. Cells were collected and counted 
at 36, 60, and 84 h using a ViCell counter (Beckman Coulter, 
Pasadena, CA). Apoptotic rate of miR-16 overexpression at 
60 and 84 h was estimated by following equation: 
Apoptotic rate   
cell count in target period ¼ 100%− x 100
ell count in previous period 
Cell proliferation assay. MCF-7 cells were cultivated at 5× 
103 in 96-well plates and incubated at 37°C for one night. 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assays was performed 36, 60, and 84 h after infec­
tion of MCF-7 cells with 25×103 recombinant or nonrecom­
binant miR-16 viral particles, 0.5 mg/mL of MTT solution 
was added to each well in 96-well plate, and incubation was 
continued for 4 h at 37°C. Then, medium was removed and 
100 μL dimethyl sulfoxide (DMSO, Sigma) was added to 
extract the dye. Finally, test and control absorbance measured 
at 570 nm with a reference filter of 570 nm. All tests were 
performed in triplicate. Inhibitory rate of miR-16 overexpres­
sion on breast cancer cells proliferation was calculated by 
following equation: inhibitory rate of cells={(OD control 
wells−OD treated wells)/OD control wells}×100%. 
Cell cycle analysis. For  assessment of cell population in dif­
ferent phases of cell cycle, flow cytometric analysis of DNA 
content was utilized for transduced or non-transduced miR-16 
virus particles 36 h after transduction as just described 
(Gharagozloo et al. 2012) briefly, cells were enzymatically 
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detached from tissue cultures, fixed with ethanol for 2 h, 
permeabilized with 0.1% Triton X-100, and labelled with 
propidium iodide (PI). Finally, the distribution of cell-cycle 
phases was evaluated by flow cytometry (FACScan; BD Bio­
sciences, San Jose, CA) and Modfit 3.0 software. 
Apoptotic assay. MCF-7 cells were infected by recombinant 
or nonrecombinant miR-16 virus particles. After incubation 
for 60 h in 37°C and 5% CO2, apoptotic cells were detected 
using an Annexin-V/PI kit (Sigma) according to the manufac­
turer ’s instruction. Then, results were analyzed by flow 
cytometry. 
Statistical analysis. All experiments were performed at least 
three times. Statistical analysis including mean and standard 
deviation (SD) were carried out using Statistical Package for 
the Social Sciences software (SPSS, v.16 for windows; SPSS 
Inc., Chicago, IL). One-way analysis of variance was used to 
compare results. The P values of ≤0.05 were considered sta­
tistically significant. Data are presented as mean±SD. 
Results 
Infection of MCF-7 cells by recombinant miR-16 lentiviruses 
leads to overexpression of miR-16. To detect the effect of 
miR-16 overexpression on proliferation and survival of cancer 
cells, we cloned the sequence of pre-miR-16 in lentiviral vec­
tors and transduced MCF-7 cells. To assess the expression 
level of miR-16, we performed miR-quantitative RT-PCR as­
say, indicating that miR-16 expression was significantly in-
creased by sixfold (P<0.05) when MCF-7 cells were infected 
by recombinant miR-16 virus. However, no remarkable dif­
ferences were observed between miR-16 expression in the 
blank control group and the group infected by nonrecombi­
nant miR-16 viruses (Fig. 1A, P<0.05).  
Overexpression of miR-16 decreased expression level of 
CCND1 and BCL2. CCND1 and BCL2 mRNAs are specific 
targets of miR-16 (Liu et al. 2008) that contains only one 
highly conserved target site for this miRNA, at position 
3130–3137 and 3741–3749 of their 3′-UTR, respectively. To 
Figure 1. Impact of miR-16 overexpression on mRNA and protein 
levels of target genes. (A) MiRNA expression level was evaluated in 
different groups using QRT-PCR. miR-16 expression was considerably 
increased by sixfold (P<0.05) when MCF-7 cells were infected by 
recombinant miR-16 virus. (B) qRT-PCR analysis of CCND1 mRNA 
level in MCF-7 cells. Overexpression of miR-16 induced a reduction in 
the CCND1 mRNA level compared to the blank control (*P<0.05). 
Western blotting analysis of CCND1 (C) and BCL2 (D) proteins  
expression in MCF-7 cell line. Ectopic expression of miR-16 induces 
significant reduction in expression level of these proteins. (E) Anti-
miR-16 transduction leads to a significant increase in the expression of 
CCND1 and BCL2 proteins. R virus recombinant miR-16 virus, N-R 
virus nonrecombinant miR-16 virus. 1Blank control group. 2Nonrecom­
binantmiR-16 infected group. 3Recombinant miR-16 infected group. All 
tests were performed in triplicate and data were presented as mean±SD. 
*P<0.05.  
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Figure 2. miR-16 reduced cell growth in MCF-7. (A) As compared to 
that of the blank control, miR-16 overexpression reduces cell growth in 
MCF-7 cell line after 36, 60, and 84 h of infection (P<0.05). (B) MTT  
results of MCF-7 cell line after miR-16 induction. miR-16 can 
considerably reduce the absorbance value of MCF-7 cells after 36, 60, 
and 84 h upon infection by recombinant miR-16 virus compared with the 
assess whether miR-16 could also regulate these targets in 
breast cancer, QRT-PCR and Western blot were performed 
for CCND1 and BCL2. qRT-PCR results in Fig. 1B indicated 
that CCND1 expression in the test group which treated with 
recombinant miR-16 viruses reduced to 48±1.34% compared 
with the expression level in the blank control group. However, 
CCND1 expression level did not differ between the blank 
control group and cells infected with nonrecombinant miR­
16 viruses (P<0.05). We also performed Western blot and 
found that the protein level of CCND1 decreased into 64% 
in MCF-7 cell line, with increased miR-16 (Fig. 1C). There 
was no differences in BCL2 mRNA expression between trans­
duced and control cells. So, BCL2 protein level was analyzed 
by Western blot and found that miR-16 overexpression dra­
matically decreased the BCL2 protein level (into 43%, 
Fig. 1D) in MCF-7 cells. Next, we inhibited endogenous 
miR-16 in MCF-7 cells by using anti-miR-16 lentiviruses. 
Globally, for both of targets, we observed a trend towards 
increase in BCL2 and CCND1 proteins, indicating that miR­
16 regulates the expression of the two endogenous targets 
analyzed in MCF-7 cells (Fig. 1E). 
miR-16 can reduce cell proliferation and induce apoptosis in 
MCF-7 cells. To study the functional roles of miR-16 
Figure 3. Phase contrast 
micrograph of MCF-7 cell lines. 
Impact of miR-16 overexpression 
on MCF-7 cells morphology and 
apoptosis by invert microscopy. 
(A) Blank control group that did 
not receive any treatment (×400); 
(B) MCF-7 cells infected with 
recombinant miR-16 virus 
(×400). 
blank control group (P<0.05), while there was no significant difference 
between the blank control and nonrecombinant miR-16 virus groups 
(P<0.05).  R virus  recombinant miR-16 virus, N-R virus nonrecombinant 
miR-16 virus. Data were shown as mean±SD of at least three separate 
tests. 
overexpression on breast cancer, we examined MCF-7 cell 
growth curve and performed MTT test, cell cycle analysis, 
and apoptosis assay. In Fig. 2A, we demonstrated that cell 
growth in MCF-7 cells infected by recombinant miR-16 vi­
ruses were significantly decreased in comparison with control 
groups after 36, 60, and 84 h. According to these results, cell 
proliferation rate in recombinant miR-16 transduced group 
was significantly reduced to 74% at 36 h, 38% at 60 h, and 
13.5% at 84 h, when compared with the blank control group. 
On the other hand, apoptotic rate of miR-16 overexpression in 
cells infected with recombinant miR-16 viruses was approxi­
mately 29 and 49%, at 60 and 84 h, respectively, comparing 
their blank controls. MTT assay results exhibited that there 
was meaningful statistical difference between the absorbance 
value of the blank control cells and cells infected with recom­
binant miR-16 viruses after 36 h (0.250 vs. 0.190), 60 h (0.370 
vs. 0.150), and 84 h (0.560 vs. 0.110). Nevertheless, no obvi­
ous changes were observed between blank control cells and 
cells which were infected with nonrecombinant miR-16 virus­
es in the same intervals: 0.250 vs. 0.248, 0.370 vs. 0.365 and 
0.560 vs. 0.556, respectively (P<0.05; Fig. 2B). Consequent­
ly, inhibitory rate of miR-16 on proliferation and survival rate 
of MCF-7 cells which infected with recombinant miR-16 vi­
ruses were 24% in 36 h, 59% in 60 h, and 80% in 84 h. As 
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Table 1. Cell cycle phase distribution of MCF-7 groups after 36 h regulated pathways disturbs the controlled proliferation and 
Cell cycle phases MCF-7 groups 













Results were reported as mean±SD 
N-R nonrecombinant miR-16 virus infected group, R recombinant miR­
16 virus-infected group 
shown in Fig. 3, miR-16 overexpression induced remarkably 
morphological changes in infected cells with recombinant 
miR-16 viruses, compared to other groups. 
Interestingly, cell cycle analysis by flow cytometry showed 
that overexpression of miR-16 triggered an increase in the num­
ber of cells in G0/G1 phase (62.08%) as compared to that of the 
blank control group (42.58%) and a reduction in the number of 
S phase cells (20.05%) as compared with the blank control 
(29.30%, Table 1). To confirm miR-16 overexpression effect 
on cell apoptosis, annexin V-PI assay was performed after 60 h 
upon infection.We found that apoptotic rate in the blank control 
group, cells treated with nonrecombinant and recombinant 
miR-16 viruses were 6.5, 8.5, and 35%, respectively, indicating 
apoptosis rate was elevated by 5.4-fold in cells infected with 
recombinant miR-16 viruses. As expected, there was no obvi­
ous difference between the blank control group and nonrecom­
binant miR-16 virus-infected cells (P<0.05, Fig.  4). 
Discussion 
Proliferation and apoptosis are two important factors in which 
regulating by abundant mechanisms ensuring correct cell di­
vision and programmed cell death. Defection in these 
differentiation of the normal cell homeostasis and conse­
quence in malignant growth. According to many literatures, 
altered expression of miRNAs has also been revealed in nu­
merous types of human cancer including breast cancer, sug­
gesting the potential of miRNAs as imperative biomarkers for 
cancer diagnosis, prognosis, and pathogenesis (Guo et al. 
2012; Harquail et al. 2012). On the other hand, miR-16 is 
the one of the main tumor suppressor miRNAs that reduces 
cell proliferation, promotes apoptosis of cancer cells, and in­
hibits tumorigenicity both in vitro and in vivo (Rivas et al. 
2012). miR-16 functions by targeting multiple oncogenes, in­
cluding BCL2 (Yang et al. 2008),  CCND1, CCNE1, and  
WNT3A. So the aim of the present study was to investigate 
the miR-16 enforced expression impact on the breast cancer 
cell behavior. Our results demonstrated that ectopic expres­
sion of miR-16 inhibits cell proliferation and induces apopto­
sis in cell line derived from breast cancer (MCF-7), efficiently 
through targeting CCND1 and BCL2, respectively. Liu Q 
et al. has shown that miR-16 regulates Cyclin D1 (CCND1), 
Cyclin D3 (CCND3), Cyclin E1 (CCNE1), and cyclin­
dependent kinase 6 (CDK6) and induces G1 arrest in A549, 
HepG6, and HeLa cell lines (Linsley et al. 2007). In the pres­
ent study, we have revealed by various methods that miR-16 
can also regulate CCND1 and induce G1 arrest in MCF-7 
cells. According to qRT-PCR and Western blot results, 
CCND1 expression in recombinant miR-16 virus-infected 
cells dramatically decreased into approximately 50 and 36%, 
respectively, when compared with that in the blank control 
group. Moreover, cell cycle analysis indicated that enforced 
expression of miR-16 inhibits the progression of G1 to S 
phase of MCF-7 cell cycle compared with the blank control 
group. Also, our experiments designated that miR-16 overex­
pression in MCF-7 cells after 36, 60, and 84 h upon infection 
with recombinant miR-16 viruses could reduce cell prolifera­
tion dramatically as compared with the blank control group. 
These results seem to be consistent with previous study by 
Figure 4 Annexin-V/PI assay results. (A) Blank control group; (B) MCF-7 cells infected by nonrecombinant miR-16 viruses; (C) MCF-7 cells infected 
by recombinant miR-16 viruses. Results were mean of three independent experiments±SD. 
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Kaddar T. et al. who found that miR-16 can negatively regu­
lates HMGA1 and caprin-1, which play important roles in the 
MCF-7 cell proliferation (Kaddar et al. 2009). In the present 
study, MCF-7 cells morphology apparently changed to spher­
ical shape with dense cytoplasm upon approximately 46 h 
after infection with recombinant miR-16 viruses. Then, de­
tached cells from plate could be observed gradually. These 
observations demonstrated that overexpression of miR-16 
has two functions: not only controls cell cycle and inhibits 
proliferation but also markedly induces apoptosis in MCF-7 
cells. Immortality is a key factor in cancer, as it permits genet­
ically unstable cells to stay alive and accumulate further mu­
tations that ultimately make possible tumorigenesis. More­
over, Cimmino A. et al. indicated that miR-16 induces apo­
ptosis in a leukemic cell line via targeting BCL2 (Kaddar et al. 
2009). BCL2 is a vital player in the programmed cell death of 
eukaryotic cells that inhibiting apoptosis and favoring surviv­
al. Anti-apoptotic role of BCL2 protein, as an oncogenic pro­
tein, was identified for the first time in follicular lymphoma on 
1984 (Tsujimoto et al. 1984; Bakhshi et al. 1985). Further 
studies demonstrated that overexpression of BCL2 protein is 
correlated with numerous type of cancers such as lymphoma, 
leukemia, lung, and breast cancer (Cory and Adams 2002; 
Youle and Strasser 2008). Until now, various studies are de­
voting to recognize and target signaling pathway of BCL2 
protein, to destroy tumor cells and reverse the phenotype of 
cancerous cells (Jovanovic and Hengartner 2006; Garofalo 
et al. 2010). For example, Guo C. et al. reported that miR­
15 and miR-16 expression are associated inversely with BCL2 
expression and that both miRNAs remarkably induce apopto­
sis by targeting BCL2 in rat hepatic satellite cells (Guo et al. 
2009). Similar to that, our Western blot results revealed that 
there was inverse correlation between the expression of miR­
16 and BCL2 protein. miR-16 negatively regulates BCL2 ex­
pression and promotes apoptosis through this way in MCF-7 
cells. Annexin V-PI analysis demonstrated that no effects were 
observed 36 h upon infection with recombinant miR-16 virus­
es (data not shown). However, miR-16 overexpression in­
creased apoptosis rate into 35%, upon culturing for 60 h. The­
se findings are disagreement with previous finding as ob­
served with Linsely P. et al. who demonstrated that miR-16 
overexpression have no effect on BCL2 level and apoptosis 
induction in SW1417, HeLa, and DLD-1 cell lines, suggesting 
that the miR-16 influence on apoptosis is cell type specific. 
Thus, miR-16 could induce apoptosis in some types of cells, 
but leads to cell cycle arrest in the others (Linsley et al. 2007). 
There were a little difference between apoptosis rate as mea­
sured by cell growth curve and apoptosis assay. These differ­
ences might due to accuracy in analysis of apoptosis by flow 
cytometry and apoptosis kit. 
Briefly, achieved data displayed that miR-16 is able to in­
duce apoptosis and cell cycle arrest in MCF-7 cells. It should 
be  noted  that  anti-proliferation effect  of miR-16  
overexpression was observed after 36 h of infection with re­
combinant miR-16 viruses, but anti-apoptotic impact was 
slowly revealed after 46 h. These observations suggest that 
anti-proliferating effect of miR-16 is not the consequence of 
apoptosis. Therefore, it is likely that both of these effects par­
ticipate in tumor suppressor activity of miR-16 in MCF-7 
cells. Taken together, these data suggest that overexpression 
of miR-16 could be considered as a useful therapeutic agent to 
treat breast cancer patients in the future. Unfortunately, our 
study was limited to just MCF-7 cells, and miR-16’s capabil­
ity to induce apoptosis and inhibit cancer cell growth should 
be assessed in not only other type of breast cancer cell lines 
and but also in normal cells. However, considering the prob­
ability of side effects in adjacent normal cell, cancer cell­
specific gene expression can be achieved by using promoters 
expressed in malignant cells, such as H19 lncRNA promoter 
(Mizrahi et al. 2009). Further in vitro and in vivo investiga­
tions in this field could open new insights in use of miRNA­
based therapy in breast cancer. 
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